Samantha Tucker-Samaras

Long Valley, New Jersey, United States Contact Info
2K followers 500+ connections

Join to view profile

Activity

Join now to see all activity

Experience & Education

  • Unilever

View Samantha’s full experience

See their title, tenure and more.

or

By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement, Privacy Policy, and Cookie Policy.

Publications

  • 4-Hexyl-1,3-phenylenediol, an NF-kB inhibitor, improves photodamaged skin and clinical signs of ageing in a double-blinded, randomised controlled trial

    British Journal of Dermatology

    Background The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
    pathway is a key mediator of inflammation; however, few studies have examined the direct
    effects of NF-κB inhibition on skin.
    Objectives To investigate NF-κB activity in cultured human fibroblasts and to investigate the
    effects of 4-hexyl-1,3-phenylenediol (an NF-κB inhibitor) on elastin and collagen gene
    expression in vitro and on the clinical appearance of photodamaged skin.
    Methods The…

    Background The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)
    pathway is a key mediator of inflammation; however, few studies have examined the direct
    effects of NF-κB inhibition on skin.
    Objectives To investigate NF-κB activity in cultured human fibroblasts and to investigate the
    effects of 4-hexyl-1,3-phenylenediol (an NF-κB inhibitor) on elastin and collagen gene
    expression in vitro and on the clinical appearance of photodamaged skin.
    Methods The amount and activity of NF-κB in human fibroblasts obtained from donors (17–78
    years old) was measured after transfection with a NF-κB reporter and luciferase promoter
    system. Expression of extracellular matrix (ECM) genes was determined using quantitative PCR.
    Women with moderate skin photodamage were randomized to daily treatment with a topical
    lotion containing 4-hexyl-1,3-phenylenediol (n = 30) or vehicle (n = 29) for 8 weeks, withclinical assessments at baseline and weeks 2, 4 and 8.
    Results Fibroblasts obtained from donors older than 50 years had higher NF-κB activity
    compared with cells from younger donors; inhibition of the NF-κB pathway with 4-hexyl-1,3-
    phenylenediol enhanced the expression of ECM genes. In women, treatment for 8 weeks with 4-
    hexyl-1,3-phenylenediol significantly improved crow’s feet, fine lines, cheek wrinkles, age
    spots, mottled pigmentation and radiance compared with both the vehicle and baseline.
    Furthermore treatment with 4-hexyl-1,3-phenylenediol resulted in a two-fold greater clinical
    improvement in overall photodamage than vehicle group.
    Conclusions Inhibition of the pro-inflammatory NF-κB pathway resulted in increased expression
    of ECM proteins in vitro and significant clinical improvement in photodamaged skin

    Other authors
    See publication

  • Cosmeceutical Ingredients. In Cosmeceuticals and Cosmetic Practice: Essential Ions and Bioelectricity in Skin Care

    Wiley-Blackwell. Farris, Patricia K. (2014).

    See publication

  • Metabolomic analysis of sun exposed skin

    Molecular BioSystems

    Other authors

Patents

  • Compositions comprising an NF-kB-inhibitor and a non-retinoid collagen promoter

    Issued US 8906432

    Invention relates to a composition comprising an NF-kB-inhibitor and a non-retinoid collagen promoter.

    Other inventors

  • Topical application of 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene

    Issued US 8,758,731

    A method of lightening skin, comprising the step of topically applying to skin in need of skin lightening treatment a composition comprising 1-hydroxyl 3,5-bis(4'hydroxyl styryl)benzene or a cosmetically acceptable salt thereof

    Other inventors

  • Compositions Compromising of Southernwood and an Amine Compound

    Issued US US8,722,113

    Other inventors

  • Compositions comprising an anti-inflammatory blend

    Issued US 8,318,217

    The present invention relates to a composition comprising an NF-kB-inhibitor and an anti-inflammatory compound. The anti-inflammatory compound is not an NF-kB-inhibitor and has an IC50 of about 70 ug/ml or less.

    Other inventors

  • Compositions and methods for treating signs of skin aging

    Issued US 8080265

    The invention relates to methods and compositions for treating skin aging, said compositions comprising at least one tropoelastin promoter and at least one tropoelastin crosslinker.

    Other inventors

  • Methods and compositions for enhancing hair quality using blackberry extract

    Filed EU 14154695.2-1458

    Other inventors

Honors & Awards

  • Johnson's Medal Winner 2013

    -

More activity by Samantha

View Samantha’s full profile

  • See who you know in common
  • Get introduced
  • Contact Samantha directly
Join to view full profile

Other similar profiles

Explore collaborative articles

We’re unlocking community knowledge in a new way. Experts add insights directly into each article, started with the help of AI.

Explore More

Add new skills with these courses

See all courses